Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma

被引:3
作者
Ohno, Tomoyoshi
Hirashima, Noboru
Orito, Etsuro
Hasegawa, Izumi
Fujiwara, Kei
Itoh, Kiyoaki
Ozasa, Atsushi
Shinkai, Noboru
Tanaka, Yasuhito
Kato, Takanobu
Ueda, Ryuzo
Sakakibara, Kenji
机构
[1] Social Insurance Chukyo Hosp, Dept Gastroenterol, Nagoya, Aichi 4578510, Japan
[2] Higashi Handa Clin, Handa, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Nagoya, Aichi 467, Japan
[4] Nagoya City Univ, Grad Sch Med Sci, Clin Mol Informat Med, Nagoya, Aichi 467, Japan
关键词
cytotoxic T lymphocyte; dendritic cells; hepatitis C virus; hepatocellular carcinoma;
D O I
10.1111/j.1872-034X.2007.00048.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: Peptide-based therapeutic vaccines are being developed. The aim of this study was to determine the feasibility of immunotherapy to hepatitis C virus (HCV)-positive hepatocellular carcinoma (HCC) by assessing the inductivity of peptide-specific cytotoxic T lymphocyte (CTL) by dendritic cells. Methods: The inductivity of CTL was characterized in six patients with HCV-positive HCC, and compared to seven healthy volunteers and six patients with chronic HCV hepatitis (control). Results: Peptide-specific CTL was comparably induced in controls, but not induced in any patients with HCC. To characterize this, the cytokine profile and the expression of surface molecules interacting between dendritic and T cells were evaluated. Among the cytokines, production of interferon (IFN)-gamma was found to be impaired and closely related to the results of CTL assays, while the expression of surface molecules showed no significant changes. Conclusions: In HCV-positive HCC patients, CTL inductivity by dendritic cells is impaired. This may be related to the impaired production of IFN-gamma.
引用
收藏
页码:276 / 285
页数:10
相关论文
共 49 条
[1]  
ALTER HJ, 1989, NEW ENGL J MED, V321, P1495
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[4]  
CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333
[5]   Analysis of a successful immune response against hepatitis C virus [J].
Cooper, S ;
Erickson, AL ;
Adams, EJ ;
Kansopon, J ;
Weiner, AJ ;
Chien, DY ;
Houghton, M ;
Parham, P ;
Walker, CM .
IMMUNITY, 1999, 10 (04) :439-449
[6]  
Cormier JN, 1997, CANCER J, V3, P37
[7]   DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese [J].
Date, Y ;
Kimura, A ;
Kato, H ;
Sasazuki, T .
TISSUE ANTIGENS, 1996, 47 (02) :93-101
[8]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[9]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[10]  
de Saint-Vis B, 1998, J IMMUNOL, V160, P1666